Ulcerative colitis
Conditions
Interventions
None listed
Sponsors
National Defense Medical College
Ohmori Toshihide Gastro-intestinal Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with active ulcerative colitis who satisfy all below requirements and over 20 years old. 1. Mayo score =>5 2. Mayo endoscopic subscore =>2 3. Patients who understood information of this study and voluntarily consented for this study
Exclusion criteria
Exclusion criteria: 1. Patients with granulocyte count 2,000/mm3 or less 2. Patients with serious infectious disease 3. Patients with proctitis 4. Patients who used of enema, suppository (mesalazine, sulfasalazine, steroids) within the last 2 weeks 5. Patients who started administration or increased the dosage of mesalazine, sulfasalazine within the last 4 weeks 6. Patients who started administration or increased the dosage of steroids (oral) within the last 2 weeks 7. Patients who received steroids (intravenous infusion) within the last 2 weeks 8. Patients who used of total parenteral nutrition within the last 4 weeks 9. Patients who received cyclosporine, tacrolimus within the last 4 weeks 10. Patients who started administration or increased the dosage of azathioprine, 6-mercaptopurine within the last 4 weeks 11. Patients who received infliximab within the last 6 weeks 12. Patients who used of GMA, LCAP within the last 8 weeks 13. Patients with history of colectomy 14. Patients with inappropriate for this study by doctor's judgement 15. Patients who refused to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mucosal healing rate (Endoscopic score of Mayo index) | — |
Secondary
| Measure | Time frame |
|---|---|
| Remission rate (Mayo score) Efficacy (Mayo score) Changes in mRNA expression levels of inflammation associated molecules in colonic mucosa | — |
Countries
Japan
Contacts
Public ContactRyota Hokari
National Defense Medical College Second Department of Internal Medicine
Outcome results
None listed